INVESTOR RELATIONS
CEO’s comment – March 21, 2025
Isofol receives regulatory approval to initiate clinical study of arfolitixorin
“This approval is a milestone and a strong validation of our strategy for the continued clinical development of arfolitixorin. We are now looking forward to initiating the study together with our partner Charité and have our sights set on the next important objective: to include the first patient. This is a significant step forward on our journey to improve the prognosis for cancer patients,”says CEO, Petter Segelman Lindqvist.
CEO, Petter Segelman Lindqvist
INVESTORS – latest reports and presentations
Media – Lates pressreleases
Isofol’s rights issue fully subscribed – exercises overallotment for Japanese partner
GOTHENBURG, Sweden, 4 July 2025 – Isofol Medical AB (“Isofol” or the “Company”) today announces the outcome of the Company’s rights issue of units…
Isofol publishes prospectus in connection with the company’s rights issue
GOTHENBURG, Sweden, 17 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol” or the “Company”) announced on…
Isofol completes first cohort in ongoing clinical study with arfolitixorin
GOTHENBURG, Sweden, June 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the first cohort in…
SEE HOW ARFOLITIXORIN
WORKS IN CANCER CELLS
About arfolitixorin
Want to know more about the the drug candidate arfolitxorin?
Last updated 03-21-2025
